Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad297 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Farouk Bouraima und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry and Molecular Genetics Department, University Hospital, 63000 Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Hypophosphatemia, Osteomalacia, Paraneoplastic Syndromes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Context
Tumor-induced osteomalacia (TIO) due to fibroblast growth factor 23 (FGF23) overexpression is becoming recognized in patients with malignancy. The condition may be underdiagnosed, with a scarce medical literature.
Objective
To perform a meta-analysis of case reports to allow a better understanding of malignant TIO and its clinical implications.
Methods
Full texts were selected according to strict inclusion criteria. All case reports were included where patients had hypophosphatemia, malignant TIO, and FGF23 blood levels. Thirty-two of 275 eligible studies (n = 34 patients) met inclusion criteria. A list of desired data was extracted and graded for methodological quality.
Results
Prostate adenocarcinoma (n = 9) were the most tumors reported. Twenty-five of 34 patients had a metastatic disease and a poor clinical outcome was reported for 15 of 28 patients. The median levels of blood phosphate and C-terminal FGF23 (cFGF23) were 0.40 mmol/L and 788.5 RU/mL, respectively. For most of patients, blood PTH was elevated or within range, and calcitriol levels were inappropriately low or normal. Alkaline phosphatase concentrations were increased for 20 of 22 patients. The cFGF23 values were significantly higher for patients with a poor clinical outcome when compared to other patients (1685 vs 357.5 RU/mL). In case of prostate cancer, cFGF23 levels were significantly lower (429.4 RU/mL) than for other malignancies (1007.5 RU/mL).
Conclusion
We report for the first time a detailed description of the clinical and biological characteristics of malignant TIO. In this context, FGF23 blood measurement would be of value for the diagnostic workup, prognostication, and follow-up of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry and Molecular Genetics Department, University Hospital, 63000 Clermont-Ferrand, France.
- Clermont Auvergne University, CNRS, INSERM, iGReD, 63000 Clermont-Ferrand, France.
- Rheumatology Department, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.
- Biostatistics unit (DRCI) Department, University Hospital, 63000 Clermont-Ferrand, France.
ORCID-Profile: Vincent Sapin, Bruno Pereira, Damien Bouvier
Zitieren
APA
Bouraima, F., Sapin, V., Kahouadji, S., Pickering, M. E., Pereira, B., Bouvier, D., & Oris, C. (2023). Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad297
Vancouver
Bouraima F, Sapin V, Kahouadji S, Pickering ME, Pereira B, Bouvier D, et al. Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad297
BibTeX
@article{Bouraima2023,
author = {Bouraima, Farouk and Sapin, Vincent and Kahouadji, Samy and Pickering, Marie-Eva and Pereira, Bruno and Bouvier, Damien and Oris, Charlotte},
title = {Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad297}
}
EUVIMED